Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023

Tixagevimab/cilgavimab is a monoclonal antibody used to prevent coronavirus disease 2019 among immunocompromised hosts and maintained neutralizing activity against early omicron variants. Omicron BN.1 became a dominant circulating strain in Korea early 2023, but its susceptibility to tixagevimab/cil...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jinyoung, Hyeon, Seokhwan, Baek, Jin Yang, Kang, Min Seo, Lee, Keon Young, Lee, Young Ho, Huh, Kyungmin, Cho, Sun Young, Kang, Cheol-In, Chung, Doo Ryeon, Peck, Kyong Ran, Won, Gunho, Lee, Hye Won, Kim, Kwangwook, Hwang, Insu, Lee, So Yeon, Kim, Byung Chul, Lee, Yoo-kyoung, Ko, Jae-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332950/
https://www.ncbi.nlm.nih.gov/pubmed/37431539
http://dx.doi.org/10.3346/jkms.2023.38.e205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332950/
https://www.ncbi.nlm.nih.gov/pubmed/37431539
http://dx.doi.org/10.3346/jkms.2023.38.e205

Ejemplares similares